“Treatment of Severe Extremity Injury Using Autologous Bone Marrow Stem Cells”
Extremity injuries are the most common battleﬁeld injuries and are often complicated by compartment syndrome (CS). These injuries occur frequently with civilian trauma. Trauma related edema and tissue swelling within muscle compartments leads to increased pressures that then cause ischemia and infarction that greatly magnify the original injury. Current treatment is emergent fasciotomy followed by a long program of surgical wound care and rehab. In many cases incomplete tissue regeneration is achieved and long-term neuromuscular disability results. Our goal is to improve the endogenous cellular regenerative response by loc al treatment with autologous bone marrow stem and progenitor cells (BM-MNC) to provide a safe improvement in functional recovery. In this talk results from a pre-clinical, prospective, randomized, blinded, sham-controlled chronic (3 month) study using BM-MNCs to treat CS performed in adult swine will be presented.
Biosketch: Dr. Gregory is the founder and director of the OHSU Center for Regenerative Medicine. His work in regenerative medicine spans from the use of autologous bone marrow stem and progenitor cells to treat severe extremity injuries complicated by compartment syndrome, stem cells for treatment of nerve and heart regeneration as well as the use of MSCs to treat acute lung injury and other inflammatory injuries. Dr. Gregory has been a Program Leader for the Armed Forces Institute of Regenerative Medicine in the area of Extremity Injury. As a Professor of Biomedical Engineering at OHSU, he is involved in the research of using of recombinant human structural elastin proteins to create new vascular conduits and stents as well as for regeneration of skin after burn injuries. As a practicing cardiologist he is also interested in developing new interventional technologies. He has developed novel hemorrhage control technologies for the battlefield and has founded two companies in this field. He has founded 4 other companies in the biotechnology sector. Dr. Gregory has over 20 issued patents and serves on numerous corporate and academic advisory boards.
reception follows at 5:00